Clinical trials: Breast Cancer, Metastatic
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
- Conditions
- Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
- Trial name
- NCT01209195
- Testing
- MM-121, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Merrimack Pharmaceuticals
Breast Cancer
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
This is a phase 1b/2 study of the safety and efficacy of sapanisertib (MLN0128) in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/human epidermal growth factor receptor 2 negative…
- Trial name
- NCT02049957
- Testing
- Sapanisertib, Fulvestrant, Exemestane
- Where
- 40 sites in United States, Belgium and 1 more
- Volunteers
- 118 people
- Sponsor
- Calithera Biosciences, Inc
Metastatic Breast Cancer
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
This study is a randomized prospective clinical trial of women with metastatic breast cancer. The purpose of the study is to test if an intervention of regular physical activity review and physical activity goal setting will…
- Trial name
- NCT01653366
- Testing
- Physical Activity Goal Setting
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Non Small Cell Lung Cancer, Breast Cancer
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer.
- Conditions
- Non Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- PTC-IMPACT (NCT06227728)
- Where
- 2 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
Metastatic Breast Cancer
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
To investigate parameters based on 18F-FES-PET/CT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HR+/HER2-MBC.
- Trial name
- NCT04992156
- Testing
- Palbociclib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Metastatic Breast Cancer, Recurrent Breast Cancer
Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)
To determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of adenovector expressing rat Her-2/neu in patients with metastatic or locally recurrent breast cancer.
- Trial name
- NCT00307229
- Testing
- adenoviral vector encoding rat Her-2/neu
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer, Leptomeningeal Metastases
Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer
The purpose of this study is to evaluate the impact of Depocyte® IT combined with the systemic standard treatment in terms of clinical and/or radiological neuromeningeal progression free survival (SSPN)
- Trial name
- DEPOSEIN (NCT01645839)
- Testing
- Liposomal Cytarabine
- Where
- 10 sites in France
- Volunteers
- 74 people
- Sponsor
- Centre Oscar Lambret
Breast Neoplasms
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic.
- Trial name
- NCT07060807
- Testing
- Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Metastatic Breast Cancer to the Brain
18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
The purpose of this study is to compare two different imaging methods to examine the response of brain metastases to WBRT. These two imaging methods will take pictures of the brain using : 1) a positron emission tomography (PET)…
- Trial name
- NCT01621906
- Testing
- 18F-FLT-PET Imaging
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer Metastatic
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
This is a randomized, open-label, multi-center, Phase II clinical study to evaluate the efficacy and safety of margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in Chinese patients (Mainland, Hong Kong…
- Trial name
- NCT04262804
- Testing
- Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine)
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Pleural Metastases, Breast Cancer
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
Cancers that have spread to the inner lining of the chest are classified as Stage IV and bear a poor prognosis. Surgery is rarely an option, with palliative chemotherapy and/or radiation therapy the only treatment options.
- Conditions
- Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer
- Trial name
- NCT01163552
- Testing
- Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Breast Cancer
Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer
RATIONALE: Measuring blood levels of tumor cells in patients with breast cancer may help doctors predict how patients will respond to treatment.
- Trial name
- NCT00898014
- Testing
- fluorescence in situ hybridization, immunologic technique, laboratory biomarker analysis
- Where
- France
- Volunteers
- 216 people
- Sponsor
- Institut Curie
Breast Cancer, Quality of Life
Breast Cancer Self-Management Mobile Care Application Intervention in the Quality of Life
The aim of this study was to investigate the quality of life (QoL) for women with breast cancer in Taiwan after using the BCSMS App.
- Trial name
- NCT04174248
- Testing
- BCSMS App
- Where
- Taiwan
- Volunteers
- 112 people
- Sponsor
- National Yang Ming Chiao Tung University
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04529044
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OHSU Knight Cancer Institute
Metastatic Breast Cancer
Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)
The primary objective is to compare the phenotype and genotype of the primary tumor with those of its metastases in order to optimize the treatment of metastatic disease, in patients presenting with first metastatic progression…
- Trial name
- NCT01956552
- Testing
- biopsy or cytopuncture
- Where
- 6 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut Curie
Breast Cancer
A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs
The purpose of this real-world study is to understand the use of palbociclib as first treatment for Hormone receptor positive (HR+) and Human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in Canada…
- Trial name
- NCT06003114
- Testing
- Palbociclib
- Where
- Canada
- Volunteers
- 472 people
- Sponsor
- Pfizer
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.